近视的患病人群在全世界范围内快速增加,关于近视的治疗方法研究已成为国际上眼科研究的热点之一.药物治疗是目前较为常用的减缓近视发展的方法,药物对近视发展的干预已成为越来越受期待的治疗方式,其中毒蕈碱拮抗剂减缓近视发展的效果已得到国内外的公认.毒蕈碱拮抗剂对不同M受体具有不同的干预途径和作用效果.本文中分析阿托品、哌仑西平、托吡卡胺和盐酸环戊通等毒蕈碱拮抗剂的药理、药效和不良反应以探究其临床应用的安全性和有效性,评估其临床价值,并对毒蕈碱拮抗剂治疗近视的应用和发展前景进行展望.“,”The myopic population is growing rapidly worldwide,the treatment of myopia become one of the hot spots in ophthalmology.Medicine therapy of myopia is now commonly used to slow down the progression of myopia,and it has already been the most expected one.Among all the drugs,the effect of muscarinic antagonists has been recognized at home and abroad.Muscarinic antagonists,according to their different M receptors,own different interventional approaches and therapeutic effects.Muscarinic antagonists,such include atropine,pirenzepine,tropicamide and cyclopentolate,their pharmacology and adverse effects are analyzed in order to explore their safety and efficacy and evaluate their clinical value.This paper reviewed these aspects of muscarinic antagonists and raise the discussion and prospect of muscarinic antagonists in the treatment of myopia.